Pfizer’s Tygacil Antibiotic Risky Even In Approved Indications, FDA Says
This article was originally published in The Pink Sheet Daily
Executive Summary
A 2010 safety communication that called attention to increased risk of death, possibly driven by off-label use, was followed by an analysis in approved indications that shows the threat is genuine across the board.